UofL CONTINUING MEDICAL EDUCATION & PROFESSIONAL DEVELOPMENT

Liver Research Consortium
Your Link to a Successful Clinical Trial

2016

Emerging Therapies for PBC, NASH and ESLD

An Evidence-Based Seminar Focused on Chronic Liver Diseases







TARGET AUDIENCE

This program is especially suited for Hepatologists, Gastroenterologists, Oncologists, Internists, Family Physicians, Transplant Surgeons as well as related Physician Assistants, Nurses, and Nurse Practitioners.

These are the providers who are primarily tasked with caring for PBC, PSC, NASH and complications of ESLD, both in the hospital and in the outpatient setting

The conference will primarily focus on the challenges of: Diagnosis; Natural history; Drug therapies; Side effect management; Hepatocellular carcinoma; Hepatic encephalopathy; Hyponatremia; Variceal bleeding and Hepatorenal syndrome.

Register Today!
http://bit.ly/liver2016

Overview of the Seminar

This seminar series will provide updates on the latest clinical research with a strong focus on patient care. Teams of local hepatology experts (physicians and mid-level providers) will provide an interdisciplinary approach to diagnosis and treatment in a classroom setting that stresses strong interaction between participants and faculty. Further, the team-based faculty promotes how optimal patient outcomes can be achieved through a team approach.

To lower the barriers to participation and increase access, the program will be offered on Saturdays in ten cities throughout the country beginning in February 2016. See attached calendar of programs.

The seminar will concentrate on three key diseases of the liver and address the latest diagnosis, treatment and care management approaches for each.

Primary Biliary Cirrhosis (PBC) is an old disease but one that is experiencing some major changes. First, the name now has a new definition (**Primary Biliary Cholangitis**) and second, a new treatment, obetacholic acid (OCA), the first new drug for the disease in 20 years. It is widely expected that this drug will be approved for use in the US in 2016 and will be a breakthrough for patients who have had an incomplete response to ursodiol (URSO).

During this breakthrough course, the studies supporting the use of OCA will be reviewed in detail to clarify when the use of the drug would be indicated, what outcomes to measure and discuss the side effects that might be seen.

Non-Alcoholic Steatohepatitis (NASH) is an epidemic in the US and is expected to be the major cause of cirrhosis in the coming decades as chronic Hepatitis C wanes. There are many unmet needs associated with this disease including simple biomarkers to help diagnose it and follow experimental therapies. Currently liver biopsy is required to diagnose NASH, which has seriously limited our understanding of the disease prevalence. Estimates range between 7 - 25 million patients in the United States and unknown numbers in the rest of the world.

Clinical experts will provide a thorough review of non-invasive diagnostic testing for the disease and discuss a number of interesting and exciting drugs that are being developed for NASH

End Stage Liver Disease (ESLD) is expected to grow in prevalence through 2020, largely due to the burden of chronic viral hepatitis that exists in our population. As these patients age, a larger number will develop decompensation events such as bleeding from esophageal varices, hepatic encephalopathy, hepatocellular carcinoma, hyponatremia and renal failure. The expected increase in number of ESLD patients will create more demand for health care providers who are able to care for this growing population, both in and out of the hospital.

This cutting edge segment will teach diagnosis and management of common complications seen in patients with ESLD. After attending this educational program, participants will be able to quickly recognize the treatable complications and use the latest therapies in a reasonable fashion.

Course Directors

Paul Pockros, MD, FACG
Director, Liver Disease Center, Scripps Clinic
Director, Clinical Research
Scripps Translational Science Institute

Catherine Frenette, MD
Medical Director for Liver Transplantation
Director, Center of Excellence for HCC
Scripps Center for Organ and Cell Transplantation

Program Highlights

- Updates on the latest clinical guidelines with strong patient-focused educational sessions.
- Introduction to rare liver diseases, such as LAL-D, and the current diagnosis and treatment approaches.
- Teams of local experts, comprised of physicians and mid-level providers, providing an interdisciplinary team approach to treatment.
- Small classroom learning environment to promote interaction with faculty and between participants.
- Engaging learning format that includes cutting-edge, evidence-based presentations, illustrative case studies, small group discussion, and the use of Audience Response technology to gauge opinion and build consensus.
- Participants can receive up to 6.0 *AMA PRA Category 1 Credits*™.
- Convenient local venues and affordable registration fees.

Educational Objectives

After attending this activity, participants should be able to:

- Summarize the causes of hepatic encephalopathy.
- Review the current therapies for PBC.
- Assess new treatment options for PBC and their appropriate use.
- Learn about diagnostic tests for NASH that may be in daily use soon.
- Discuss the importance of liver biopsy for assessment of PSC, LAL-D and NASH.
- Determine the prevalence of NASH in the United States.
- Follow current guidelines for management of PBC, PSC and NASH.
- Update the information available on new treatments for these disorders using evidence-based literature.
- Assess treatment options, including the use of non-absorbable antibiotics and lactulose therapies.
- Perform the appropriate and routine diagnostic tests required to ensure early diagnosis of hepatocellular carcinoma (HCC).
- Integrate newer treatment options for HCC including the use of tyrosine kinase inhibitors.
- Identify the multiple causes for renal insufficiency in patients with ESLD including diuretic overuse, GI bleeding, systemic infection, hepatic decompensation, and hepatorenal syndromes type 1 and 2.
- Determine the risks for hyponatremia in the ESLD patient and the options for management including the use of vasopressin antagonists.
- Follow the guidelines for diagnosis and management of ascites in patients with ESLD including diuretics, therapeutic paracentesis, and transjugular intrahepatic portasystemic shunt (TIPS).
- Evaluate real-life cases which exemplify many of the complications of ESLD seen in a liver transplant center.

Registration Information

	Early Bird	Regular Registration
Physicians	$95	$115
Nurses, PA's and NP's	$60	$75
Medical Residents & Fellows	$50	$65

Early Bird Registration *ends Tuesday prior to program date.*
Regular Registration *begins Wednesday prior to through program date.*

Cancellation Policy – Requests for cancellation must be submitted to CME&PD@louisville.edu at least seven (7) days prior to the program. Such requests will receive a full refund less a $20 processing fee.

Registration fee includes course tuition, access to online conference materials, WiFi in the meeting space, breakfast, breaks and lunch. Fee does NOT include travel costs, lodging and parking.

Joint Provider Statement

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Louisville and the SC Liver Research Consortium. The University of Louisville is accredited by the ACCME to provide continuing education for physicians.

UNIVERSITY OF LOUISVILLE
CONTINUING MEDICAL EDUCATION & PROFESSIONAL DEVELOPMENT

Designation Statement

Physicians (MD/DO) - The University of Louisville Office of Continuing Medical Education & Professional Development designates this live activity for a maximum of 6.0 *AMA PRA Category 1 Credit(s)*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses - This program has been approved by the Kentucky Board of Nursing for 7.2 continuing education credits through University of Louisville Hospital, provider number 4-0068-7-16-878. The Kentucky Board of Nursing approval of an individual nursing education provider does not constitute endorsement of program content.

Nurse Practitioners - AANP accepts Category I credit from *AMA PRA Category 1 Credit(s)*™ organizations accredited by ACCME.

Physician Assistants - AAPA accepts Category I credit from *AMA PRA Category 1 Credit(s)*™ organizations accredited by ACCME.

Disclosure

Commercial Support

This course is supported, in part, by educational grants from industry, in accordance with ACCME accreditation Standards for Commercial Support. At the time this brochure was developed, a complete listing of commercial supporters is not available. Appropriate acknowledgement will be given to all supporters at the time of the educational activity.

Faculty Disclosure

In accordance with the ACCME Standards for Commercial Support, course directors, planning committees, faculty and all others in control of the educational content of the CME activity must disclose all relevant financial relationships with any commercial interest that they or their spouse/partner may have had within the past 12 months. If an individual refuses to disclose relevant financial relationships, they will be disqualified from being a part of the planning and implementation of this CME activity. Employees of a commercial interest with business lines or products relating to the content of the CME activity will not participate in the planning or any accredited portion of the conference. Disclosure will be made to all participants at the conference location, prior to the educational activity commencement.

PROGRAM AGENDA

7:30 am	*Registration, Continental Breakfast & View Exhibits*
8:00 am	**End Stage Liver Disease: Case Presentations, Managing Complications** > Treatment of hepatic encephalopathy > Treatment of ascites, edema and hepatorenal syndrome > Management of esophageal varices
8:45 am	**Hepatocellular Carcinoma** > Screening diagnostic serum assays and imaging tests > Diagnosis without histology > Treatment and management options
9:30 am	**Liver Transplantation** > Listing criteria > MELD Exceptions > Long Term Complications > Outcomes
10:15 am	*Break & View Exhibits*
10:30 am	**New Treatments for PBC** > Ursodiol > Obeticholic Acid
11:15 am	**PSC** > Epidemiology > Predicting Outcomes > Improving Survival
12:00 pm	*Lunch & View Exhibits*
12:45 pm	**NAFLD, LAL and NASH** > Epidemiology > Demographics > Diagnosis > Conventional treatments
1:30 pm	**NASH Treatments in Development** > Obeticholic Acid > Elafibranor (GTR505) > Others
2:15 pm	**Case Presentations:** > PBC > LAL causing fatty liver disease > NASH
3:00 pm	*Summary, Wrap-Up and Adjourn*

To request disability arrangements, contact CME&PD@louisville.edu at least 10 days prior to the conference. Continuing Health Sciences Education fully complies with the legal requirements of the ADA and the rules and regulations thereof.

The Seminar Sponsors

The mission of the **University of Louisville** Continuing Medical Education and Professional Development program (CME & PD) is to facilitate the needs of physicians and other healthcare team members as they seek self-improvement through life-long learning. By guiding the development and accreditation of courses that address evidence-based medical practice and expert opinion, our goals of providing opportunities for positive changes in professional competence, personal performance and medical outcomes in patient care will be met. For more information visit http://louisville.edu/medicine/cme

UNIVERSITY OF LOUISVILLE
CONTINUING MEDICAL EDUCATION & PROFESSIONAL DEVELOPMENT

The SC Liver Research Consortium (SCLRC) is an organization of physicians specializing in hepatology and gastroenterology clinical research. SCLRC's mission is to team research sponsors and SCLRC's over 80 research sites together to provide faster, higher-quality research results compared to the current "conventional" sponsor-site arrangement. This is accomplished by providing streamlined contract and budget negotiations, access to our scientific expertise in study design, efficient site selection, and ongoing site evaluation. Each year, the SC Liver Research Consortium, in collaboration with recognized CME providers, organizes national continuing medical education events about the latest research and treatment approaches for diseases of the liver. For more information visit www.scliver.com

Liver Research Consortium
Your Link to a Successful Clinical Trial



Hilton Houston Plaza/Medical Center
6633 Travis Street
Houston, TX

Howard P. Monsour, Jr., MD
Houston Methodist Hospital

John M. Vierling, MD
Baylor College of Medicine

Maura Smith, AGACNP-CB
Houston Methodist Hospital

Seattle Science Foundation
550 17th Avenue, James Tower
Seattle, WA

Kris Kowdley, MD
Swedish Medical Center

Robert Carithers, MD
University of Washington
Medical Center

Ann Croghan, PA-C
Swedish Medical Center



Clinical & Translational
Research Center
505 S. Hancock Street
Louisville, KY

Craig McClain, MD
University of Louisville
School of Medicine

Matthew Cave, MD
University of Louisville

Barbra Cave, APRN, FNP-BC
University of Louisville



Embassy Suites LAX – North
9801 Airport Blvd
Los Angeles, CA

Tse-Ling Fong, MD
University of Southern California
School of Medicine

Tram Tran, MD
Cedars-Sinai Medical Center

Lucy Mathew, NP
Cedar Sinai Medical Center



Sheraton Lincoln Harbor Hotel
500 Harbor Boulevard
Weehawken, NJ

Ira Jacobson, MD
Mt. Sinai Beth Israel Medical Center

Robert Brown, Jr., MD, MPH
Columbia University

Mary Olson, DNP
Mt. Sinai Beth Israel Medical Center



Sheraton Miami Airport Hotel
3900 NW 21st Street
Miami, FL

Christopher O'Brien, MD
University of Miami
School of Medicine

Lennox Jeffers, MD
VA Medical Center, Miami

Kay Sornmayura, DNP, ARNP-BC
University of Miami School of Medicine



Courtyard Chicago Downtown/
Magnificent Mile
65 East Ontario Street
Chicago, IL

Nancy Reau, MD
Rush Medical Center

Scott Cotler, MD
Loyola Medical Center

Vicki Shah PA-C, MMS
Rush Medical Center



DoubleTree SFO North
5000 Sierra Point Parkway
Brisbane, CA

Danielle Brandman, MD
University of California,
San Francisco Medical Center

Todd Frederick, MD
California Pacific Medical Center

Kerry Decker, RN, MSN, APN-BC
University of California,
San Francisco Medical Center



Embassy Suites Alexandria – Old Town
1900 Diagonal Road
Alexandria, VA

Zobair Younossi, MD
Inova Medical Center

Kirti Shetty, MD
John Hopkins University
School of Medicine

Brian Lam, PA-C
Inova Medical Center

DoubleTree San Diego-Del Mar
11915 El Camino Real, San Diego, CA

Catherine Frenette, MD
Scripps Center for Cell and
Organ Transplantation

Rohit Loomba, MD, MHSci
University of California
San Diego Medical Center

Heather Patton, MD, AGAF
Southern California Permanente
Medical Group